https://orcid.org/0000-0002-5629-9270
Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
AHM Safayet Ullah Prodhan, Dewan Zubaer Islam, Shahad Saif Khandker, Mohd Raeed Jamiruddin, Adnan Abdullah, Brian Godman, Sylvia Opanga, Santosh Kumar, Paras Sharma, Nihad Adnan, Alice Pisana & Mainul Haque. (2023) Breast Cancer Management in the Era of Covid-19; Key Issues, Contemporary Strategies, and Future Implications. Breast Cancer: Targets and Therapy 15, pages 51-89.
Read now
Read now
Zhiwei Zheng, Xiaobing Song, Guodong Qiu, Siqi Xu & Hongfu Cai. (2023) Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China. Current Medical Research and Opinion 39:3, pages 433-440.
Read now
Read now
Brian Godman, Andrew Hill, Steven Simoens, Gisbert Selke, Iva Selke Krulichová, Carolina Zampirolli Dias, Antony P Martin, Wija Oortwijn, Angela Timoney, Lars L Gustafsson, Luka Voncina, Hye-Young Kwon, Jolanta Gulbinovic, Dzintars Gotham, Janet Wale, Wânia Cristina Da Silva, Tomasz Bochenek, Eleonora Allocati, Amanj Kurdi, Olayinka O. Ogunleye, Johanna C Meyer, Iris Hoxha, Admir Malaj, Christian Hierländer, Robert Sauermann, Wouter Hamelinck, Guenka Petrova, Ott Laius, Irene Langner, John Yfantopoulos, Roberta Joppi, Arianit Jakupi, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Jf (Hans) Piepenbrink, Vincent de Valk, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Jurij Fürst, Dominik Tomek, Mercè Obach Cortadellas, Corinne Zara, Caridad Pontes, Stuart McTaggart, Tracey-Lea Laba, Øyvind Melien, Durhane Wong-Rieger, SeungJin Bae & Ruaraidh Hill. (2021) Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 527-540.
Read now
Read now
Articles from other publishers (23)
Ruzica Bojcic, Mate Todoric & Livia Puljak. (2024) Most systematic reviews reporting adherence to AMSTAR 2 had critically low methodological quality: a cross-sectional meta-research study. Journal of Clinical Epidemiology 165, pages 111210.
Crossref
Crossref
Sadeq Rezaei & Majid Babaei. (2023) A systematic literature review on direct and indirect costs of triple-negative breast cancer. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Crossref
Emmanuel O. Simonyan, Joke.A. Badejo & John S. Weijin. (2023) Histopathological breast cancer classification using CNN. Materials Today: Proceedings.
Crossref
Crossref
Qiyou Wu, Zhitao Wang, Xin Wang, Hui Yu & Jing Sun. (2023) Patients’ Perceptions of Biosimilars: A Systematic Review. BioDrugs 37:6, pages 829-841.
Crossref
Crossref
Hannah Jayne Moir. (2023) Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer. EMJ Oncology, pages 2-11.
Crossref
Crossref
Catherine Pham, Fang Niu, Thomas Delate, Gary L. BuchschacherJrJr, Yan Li, Ekim Ekinci, Kim Le & Rita L. Hui. (2023) Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer. BioDrugs.
Crossref
Crossref
Zhengwei Gui, Piao Liu, Dong Zhang & Wanju Wang. (2023) Clinical implications and immune implications features of TARS1 in breast cancer. Frontiers in Oncology 13.
Crossref
Crossref
Joël Ladner, Farah Madi, Roshel Jayasundera, Joseph Saba & Etienne Audureau. (2023) Phone contacts and treatment discontinuation predict survival cancer patients in a subsidized drug access program. Journal of Comparative Effectiveness Research 12:7.
Crossref
Crossref
Sayanta Thakur. (2023) Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?. Indian Journal of Surgical Oncology.
Crossref
Crossref
Hye-Young Kwon & Brian Godman. (2023) Editorial: Pharmaceutical policy, impact and health outcomes. Frontiers in Pharmacology 14.
Crossref
Crossref
Ntobeko Magnate Mpanza, Brian Godman, Mothobi Godfrey Keele & Moliehi Matlala. (2023) Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries. BMC Public Health 23:1.
Crossref
Crossref
Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu & Chuanben Chen. (2023) Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. Frontiers in Pharmacology 13.
Crossref
Crossref
Sébastien Morin, Giulia Segafredo, Manuele Piccolis, Aditi Das, Meghmala Das, Nicola Loffredi, Amina Larbi, Kim Mwamelo, Elena Villanueva, Sandra Nobre & Esteban Burrone. (2023) Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. The Lancet Global Health 11:1, pages e145-e154.
Crossref
Crossref
Saeed Mohammadpour, Samira Soleimanpour, Javad Javan-Noughabi, Nasrin Aboulhasanbeigi Gallehzan, Ali Aboutorabi, Reza Jahangiri, Rafat Bagherzadeh, Julia F. Gorman & Ali Nemati. (2022) A systemmatic literature review on indirect costs of women with breast cancer. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Crossref
Roderick T. Stark, Dominic R. Pye, Wenyi Chen, Oliver J. Newton, Benjamin J. Deadman, Philip W. Miller, Jenny-Lee Panayides, Darren L. Riley, Klaus Hellgardt & King Kuok (Mimi) Hii. (2022) Assessing a sustainable manufacturing route to lapatinib. Reaction Chemistry & Engineering 7:11, pages 2420-2426.
Crossref
Crossref
Chai Hong Rim, Won Jae Lee, Bekhzood Musaev, Ten Yakov Volichevich, Ziyayev Yakhyo Pazlitdinovich, Hye Yoon Lee, Tillysshaykhov Mirzagaleb Nigmatovich & Jae Suk Rim. (2022) Comparison of Breast Cancer and Cervical Cancer in Uzbekistan and Korea: The First Report of The Uzbekistan–Korea Oncology Consortium. Medicina 58:10, pages 1428.
Crossref
Crossref
Yongzhao Xu, Matheus A. dos Santos, Luís Fabrício F. Souza, Adriell G. Marques, Lijuan Zhang, José Jerovane da Costa Nascimento, Victor Hugo C. de Albuquerque & Pedro P. Rebouças Filho. (2022) New fully automatic approach for tissue identification in histopathological examinations using transfer learning. IET Image Processing 16:11, pages 2875-2889.
Crossref
Crossref
Xiaoyan Liu, Yitian Lang, Qingqing Chai, Yan Lin, Yahui Liao & Yizhun Zhu. (2022) Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Eleni Triantafyllidi & John K. Triantafillidis. (2022) Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. Biomedicines 10:8, pages 2045.
Crossref
Crossref
Ruijia Chen, Yalan Zhang, Kongying Lin, Defu Huang, MaoJin You, Yanjin Lai, Jinye Wang, Yingying Hu & Na Li. (2022) Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Frontiers in Pharmacology 13.
Crossref
Crossref
Soraya Ahmadi-Baloutaki, Abbas Doosti, mojtaba Jaafarinia & Hamedreza Goudarzi. (2022) Editing of the MALAT1 Gene in MDA-MB-361 Breast Cancer Cell Line using the Novel CRISPR Method. journal of ilam university of medical sciences 30:2, pages 18-31.
Crossref
Crossref
Mostafa Shanbehzadeh, Hadi Kazemi-Arpanahi, Mohammad Bolbolian Ghalibaf & Azam Orooji. (2022) Performance evaluation of machine learning for breast cancer diagnosis: A case study. Informatics in Medicine Unlocked 31, pages 101009.
Crossref
Crossref
Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin & Johanna C Meyer. (2021) Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research 10:12, pages 1019-1052.
Crossref
Crossref